Detalhe da pesquisa
1.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
J Neurol Neurosurg Psychiatry
; 95(5): 392-400, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963723
2.
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
Mult Scler
; 27(12): 1864-1874, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33464149
3.
COVID-19 in multiple sclerosis: The Dutch experience.
Mult Scler
; 26(10): 1256-1260, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662742
4.
Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Neurol Sci
; 40(12): 2555-2564, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321625
5.
Response to letter 'Lymphocyte counts and the risk of COVID-19 in people with MS'.
Mult Scler
; 27(10): 1626-1627, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064043
6.
Response to Grech et al.: FLOUX-PMS study sample considerations.
Mult Scler
; 25(13): 1820-1821, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538547
7.
Cerebral white matter blood flow and energy metabolism in multiple sclerosis.
Mult Scler
; 19(10): 1282-9, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23428956
8.
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Neurology
; 97(16): e1560-e1570, 2021 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433679
9.
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
Neurology
; 95(6): e745-e754, 2020 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32690785
10.
Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders.
J Neurol Sci
; 267(1-2): 3-16, 2008 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17935736
11.
Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.
Psychiatry Res
; 164(3): 274-82, 2008 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-19017554
12.
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.
Neurosci Lett
; 402(1-2): 22-4, 2006 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-16644118
13.
Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
J Neurol Sci
; 231(1-2): 41-4, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15792819
14.
Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
Neurology
; 89(9): 970-972, 2017 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28768850
15.
Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance.
J Cereb Blood Flow Metab
; 28(10): 1645-51, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18594554
16.
Therapeutic potential of fluoxetine in neurological disorders.
CNS Neurosci Ther
; 14(2): 153-64, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18482027
17.
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.
Eur Radiol
; 16(2): 489-95, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16028056
18.
Relationships between brain water content and diffusion tensor imaging parameters (apparent diffusion coefficient and fractional anisotropy) in multiple sclerosis.
Eur Radiol
; 16(4): 898-904, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16331463
19.
1H Magnetic resonance spectroscopy of the internal capsule in human brain: a feasibility study to detect lactate following contralateral motor activity.
Eur Radiol
; 15(7): 1349-52, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15627177
20.
Visual stimulation, 1H MR spectroscopy and fMRI of the human visual pathways.
Eur Radiol
; 15(1): 47-52, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15480690